Familial infantile bilateral striatal necrosis

Familial infantile bilateral striatal necrosis (IBSN) is a rare inherited neurodegenerative disorder characterized by symmetrical degeneration of the caudate nucleus and putamen (collectively known as the striatum) in the basal ganglia of the brain. This condition is also referred to as infantile bilateral striatal necrosis or familial striatal degeneration. The disease primarily affects the central nervous system, leading to progressive movement abnormalities and neurological decline beginning in infancy or early childhood. Clinical features typically include progressive dystonia (involuntary muscle contractions causing abnormal postures), choreoathetosis (irregular writhing movements), spasticity, developmental regression, and failure to achieve motor milestones. Affected children may also experience dysphagia (difficulty swallowing), dysarthria (difficulty speaking), and progressive cognitive decline. Brain MRI characteristically shows bilateral symmetric lesions in the striatum, often with necrosis. Some forms of the condition have been associated with mutations in the NUP62 gene or mitochondrial dysfunction, though genetic heterogeneity exists. There is currently no cure or disease-modifying treatment for familial infantile bilateral striatal necrosis. Management is supportive and symptomatic, focusing on physical therapy, occupational therapy, management of dystonia with medications such as baclofen or benzodiazepines, nutritional support, and speech therapy. The prognosis is generally poor, with many affected individuals experiencing significant disability. Genetic counseling is recommended for affected families to understand recurrence risks and inheritance patterns.

Common questions about Familial infantile bilateral striatal necrosis